MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news

<p><span style="font-weight: 400;">This week we cover a new treatment submission to the FDA for the prevention of diabetes; The launch of a</span> <span style="font-weight: 400;">bupivacaine implant to treat post op pain; The DEA schedules a newly approved opioid; The FDA classifies over 200 drugs as essential and wants manufacturers to ramp up production; And more news on drugs that are in the pipeline.</span></p>